70 related articles for article (PubMed ID: 20540880)
1. [Relation between selenium plasma levels and different prostatic pathologies].
López Fontana CM; Pérez Elizalde RF; Vanrell MC; Recalde GM; Uvilla AL; López Laur JD
Actas Urol Esp; 2010 Jul; 34(7):625-9. PubMed ID: 20540880
[TBL] [Abstract][Full Text] [Related]
2. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
3. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
5. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
6. Blood and tissue selenium concentrations and glutathione peroxidase activities in patients with prostate cancer and benign prostate hyperplasia.
Zachara BA; Szewczyk-Golec K; Tyloch J; Wolski Z; Szylberg T; Stepien S; Kwiatkowski S; Bloch-Boguslawska E; Wasowicz W
Neoplasma; 2005; 52(3):248-54. PubMed ID: 15875088
[TBL] [Abstract][Full Text] [Related]
7. Serum selenium level and prostate cancer: a case-control study.
Pourmand G; Salem S; Moradi K; Nikoobakht MR; Tajik P; Mehrsai A
Nutr Cancer; 2008; 60(2):171-6. PubMed ID: 18444148
[TBL] [Abstract][Full Text] [Related]
8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
9. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
10. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
11. Selenium levels of patients with newly diagnosed prostate cancer compared with control group.
Lipsky K; Zigeuner R; Zischka M; Schips L; Pummer K; Rehak P; Hubmer G
Urology; 2004 May; 63(5):912-6. PubMed ID: 15134980
[TBL] [Abstract][Full Text] [Related]
12. The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
De Nunzio C; Trucchi A; Miano R; Stoppacciaro A; Fattahi H; Cicione A; Tubaro A
J Urol; 2009 Mar; 181(3):1069-74; discussion 1074-5. PubMed ID: 19150546
[TBL] [Abstract][Full Text] [Related]
13. Selenium and selenomethionine levels in prostate cancer patients.
Nyman DW; Suzanne Stratton M; Kopplin MJ; Dalkin BL; Nagle RB; Jay Gandolfi A
Cancer Detect Prev; 2004; 28(1):8-16. PubMed ID: 15041072
[TBL] [Abstract][Full Text] [Related]
14. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
15. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
16. A long follow-up on prostate specific antigen density and prostate biopsy.
Netto Júnior NR; De Lima ML; Lavoura Júnior Nda S; Apuzzo F; De Lucena RG
Arch Esp Urol; 1998 Dec; 51(10):1050-3. PubMed ID: 9951132
[TBL] [Abstract][Full Text] [Related]
17. Serum selenium and subsequent risk of prostate cancer.
Nomura AM; Lee J; Stemmermann GN; Combs GF
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):883-7. PubMed ID: 11008904
[TBL] [Abstract][Full Text] [Related]
18. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk.
Goodman GE; Schaffer S; Bankson DD; Hughes MP; Omenn GS;
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1069-76. PubMed ID: 11588133
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer and adiponectin.
Goktas S; Yilmaz MI; Caglar K; Sonmez A; Kilic S; Bedir S
Urology; 2005 Jun; 65(6):1168-72. PubMed ID: 15922427
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
